1. 106491598 一种甲磺酸阿比多尔的药物制剂及其制备方法与应用
CN
15.03.2017
A61K 31/4045 Loading...
A61K 31/4045
Loading...
102016000763671
江苏吴中医药集团有限公司苏州制药厂
陈言德
A61K 31/4045
Loading...
本发明提供了一种甲磺酸阿比多尔的药物制剂及其制备方法与应用，所述药物制剂由有效剂量的一水合甲磺酸阿比多尔和药学上可接受的赋形剂组成。本发明的药物制剂通过采用一水合甲磺酸阿比多尔为主药，利用其在25℃水中的溶解度高达50～100mg/mL的优势，可增强甲磺酸阿比多尔在水溶液中的分散性，以促进药物吸收，提高药物的生物利用度；优选地一水合甲磺酸阿比多尔是以晶型C的形态存在，该晶型稳定性好，易于保存，满足制剂技术的要求。另外本发明所述的制备方法具有工艺简单和易于操作的优点。
2. 106366029 一种一水合甲磺酸阿比多尔晶型C及其制备方法与应用
CN
01.02.2017
C07D 207/22 Loading...
C07D 207/22
Loading...
201610693776.5
江苏吴中医药集团有限公司苏州制药厂
陈言德
C07D 207/22
Loading...
本发明提供了一种一水合甲磺酸阿比多尔晶型C及其制备方法与应用，该晶型C以2θ±0.2°衍射角表示的XRPD图谱在6.183°、7.858°、18.290°、18.566°、21.465°、21.717°、23.934°、24.633°、25.011°、25.617°、26.013°和31.382°处有特征衍射峰，且其水溶性好，在25℃水中的溶解度为50～100mg/mL，能够满足制剂技术的要求，使得本发明所述的一水合甲磺酸阿比多尔晶型C作为抗病毒药物具有稳定性高、抗流感病毒疗效好且毒性小的优点。本发明的制备方法具有工艺简单、易于操作且稳定性好的优点。
3. 103993057 重组人血管内皮抑素的诱导表达方法
CN
04.01.2017
C12P 21/02 Loading...
C12P 21/02
Loading...
102014000234285
江苏吴中医药集团有限公司苏州中凯生物制药厂
荣志刚
C12P 21/02
Loading...
本发明的重组人血管内皮抑素的诱导表达方法，将工程菌发酵至发酵液OD600值为10‑15，向其中加入诱导剂IPTG、碳源物质以及氮源物质，使发酵液中IPTG的浓度为0.2‑0.4mmol/L，在30‑37℃下，培养2.5‑3.5h，再向其中加入终浓度为0.1‑0.3mmol/L的诱导剂IPTG，继续培养3‑5h，即可。本发明的重组人血管内皮抑素的诱导表达方法，可满足重组人血管内皮抑素的大规模生产的需要，在较高菌体浓度下实现高效诱导表达。
4. 103992400 重组人血管内皮抑素的复性液及其制备、使用方法
CN
04.01.2017
C07K 14/475 Loading...
C07K 14/475
Loading...
102014000235202
江苏吴中医药集团有限公司苏州中凯生物制药厂
荣志刚
C07K 14/475
Loading...
本发明的重组人血管内皮抑素的复性液，包括以下成分：盐酸胍、还原型谷胱甘肽、氧化型谷胱甘肽以及络合剂，所述复性液的pH值为4.0‑5.0。本发明还提供了所述重组人血管内皮抑素的复性液的制备及使用方法。本发明的重组人血管内皮抑素的复性液，可实现重组人血管内皮抑素的高复性率，进而保证重组人血管内皮抑素的大规模生产。
5. 105646625 一种卡培他滨的制备方法
CN
08.06.2016
C07H 19/06 Loading...
C07H 19/06
Loading...
201511010118.3
江苏吴中医药集团有限公司
武卫
C07H 19/06
Loading...
本发明属于药物化学领域，具体涉及一种卡培他滨的制备方法。首先，该制备方法依次经过硅烷化、糖苷化、酰化、酯化和脱保护的步骤，中间体无需分离纯化，一锅法合成，通过萃取、重结晶即可分离纯化得到终产物卡培他滨，反应操作简便；其次，糖苷化反应中，以BF3·OEt2为Lewis酸，生产成本较低、反应原料毒性较小；再次，硅烷化反应中，以三甲基氯硅烷为硅烷化试剂，以二氯甲烷为溶剂，以碳酸钾为缚酸剂，反应结束后容易除去，有利于下步反应的进行；此外，该制备方法中硅烷化、糖苷化、酰化和酯化各反应步骤的反应温度均为20～30℃，反应条件温和。
6. 105646273 一种乌苯美司的合成方法
CN
08.06.2016
C07C 237/20 Loading...
C07C 237/20
Loading...
201410417500.5
江苏吴中苏药医药开发有限责任公司
武卫
C07C 237/20
Loading...
本发明属于药物制备领域，提出了一种全新的乌苯美司制备方法。所述的制备方法包括首先将起始原料(2S，3R)-3-氨基-2-羟基-4-苯基丁酸(简称AHPA)上的氨基用二碳酸二叔丁酯保护形成Boc保护物，再与L-亮氨酸叔丁酯缩合，最后在氯化氢的有机溶液中脱去保护基得到乌苯美司。本发明采用的合成路线使用的试剂均为常用试剂，已有工业化生产且价格低廉；反应溶剂均为普通溶剂，毒性低，对环境污染少；各步反应的条件温和，操作简便，不需要特殊的设备，适合进行工业化生产。制得的产品纯度达99.5％以上。
7. 105535928 一种高生物利用度匹多莫德的口服液体制剂及其制备方法
CN
04.05.2016
A61K 38/05 Loading...
A61K 38/05
Loading...
201510989227.8
江苏吴中医药集团有限公司
王丹梅
A61K 38/05
Loading...
本发明公开了一种高生物利用度匹多莫德的口服液体制剂及其制备方法，所述口服液体制剂，以重量份计，包括，匹多莫德300～500份；促吸收稳定剂2000～8000份；化学稳定剂1～4份；pH值调节剂150～250份；所述促吸收稳定剂为癸酸钠和山梨醇，其中癸酸钠和山梨醇的质量比为1-4：1-4。本发明的口服液体制剂通过合理设置所述匹多莫德、促吸收稳定剂、载体、化学稳定剂以及pH调节剂等组分的含量，使各组分之间的协同作用，给主药匹多莫德提供高生物利用度、利于其储存的pH值环境，从而使得匹多莫德在体内有较高的血药浓度，提高了其生物利用度，同时使得产品具有极高的稳定性，并且可以稳定储存。
8. 105434371 一种卡络磺钠冻干粉针剂及其制备方法
CN
30.03.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
201511009491.7
江苏吴中医药集团有限公司
刘凤珍
A61K 9/19
Loading...
本发明属于药物制剂领域，具体涉及一种卡络磺钠冻干粉针剂及其制备方法。本发明所述卡络磺钠冻干粉针剂的原料组成为：卡络磺钠10-50重量份和注射用水1800-2200体积份；该冻干粉针剂外观性状良好(橙黄色冻干块状物或粉末)，且杂质含量较低，在高温和光照条件下杂质含量变化较小，卡络磺钠的含量稳定，质量稳定性较好。该卡络磺钠冻干粉针剂的制备方法，通过对冷冻干燥处理采用程序升温的步骤，实现了对升温速度的控制，使得卡络磺钠在这种阶梯性的温度变化环境中充分冻干成型，获得了良好的外观性状和较好的质量稳定性；此外，该制备方法仅仅需要进行冷冻干燥少于17h，大大缩短了冷冻干燥时间，有利于工业化生产。
9. 105434372 一种利奈唑胺冻干粉针剂及其制备方法
CN
30.03.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
201511009492.1
江苏吴中医药集团有限公司
邓银来
A61K 9/19
Loading...
本发明属于药物制剂领域，具体涉及一种利奈唑胺冻干粉针剂及其制备方法。该利奈唑胺冻干粉针剂，其原料组成仅仅包括利奈唑胺和注射用水，大大减少了辅料的使用，降低了辅料所带来的安全隐患，利奈唑胺的含量稳定，质量稳定性较好，提高了该药物使用的安全性；该利奈唑胺冻干粉针剂的制备方法，通过对冷冻干燥处理采用程序升温的步骤，实现了对升温速度的控制，使得所述利奈唑胺在这种阶梯性的温度变化环境中充分冻干成型，获得了良好的外观性状和较好的质量稳定性。
10. 105061395 一种西他沙星水合物的制备方法
CN
18.11.2015
C07D 401/04 Loading...
C07D 401/04
Loading...
201510483646.4
江苏吴中医药集团有限公司
陈言德
C07D 401/04
Loading...
本发明提供了一种西他沙星水合物的制备方法，该方法是以化合物II为原料，依次经历脱苄、取代、氯化、脱叔丁氧羰基，最终制得西他沙星水合物。本发明的制备方法避免使用氢气和高压釜，大大简化了工艺操作，同时也消除了安全隐患；本发明中各工艺步骤的反应迅速，无副反应发生，且分离纯化简便快捷，使得本发明的制备方法不仅收率高，更重要的是还具有绿色环保、工艺简单、及成本低的优势，能够满足工业化大规模生产需求。
11. 103993058 Method for extracting and purifying recombinant human endostatin
CN
20.08.2014
C12P 21/02 Loading...
C12P 21/02
Loading...
201410234509.2
江苏吴中医药集团有限公司苏州中凯生物制药厂
荣志刚
C12P 21/02
Loading...
The invention relates to a method for extracting and purifying recombinant human endostatin. The method comprises the following steps of fermenting engineering strains, crushing the engineering strains, washing inclusion bodies, carrying out denaturing purification on the recombinant human endostatin, renaturing the denatured recombinant human endostatin, standing the renatured recombinant human endostatin and carrying out chromatographic separation on the recombinant human endostatin. According to the method, the condition that efficient induced expression is achieved at relatively high thallus concentration can be realized during the fermentation of the engineering strains, and a relatively high renaturation ratio is achieved during the renaturation of the denatured recombinant human endostatin, so that the large-scale production of the recombinant human endostatin is realized.
12. 203753666 一种粉针剂避光包装组合
CN
06.08.2014
B65D 85/42 Loading...
B65D 85/42
Loading...
201420130176.4
江苏吴中医药集团有限公司
孙田江
B65D 85/42
Loading...
本实用新型涉及一种粉针剂避光包装组合，包括：药物瓶，用于保存粉针剂药物；溶媒瓶，用于保存所述粉针剂药物的专用溶媒；固定座，所述固定座上设有用于固定所述药物瓶和所述溶媒瓶的凹槽；还包括适于装套所述药物瓶和所述溶媒瓶的遮光袋，所述遮光袋具有开口，在所述开口处设有用于密封所述遮光袋的接合部，在所述遮光袋的内壁设有防滑缓冲层。本实用新型的粉针剂避光包装组合，既能实现粉针剂药物与专用溶媒良好的相容性，方便临床使用，又能对药物进行避光保存、在贮藏过程中可实现保持良好的稳定性。
13. 203740289 一种粉针剂复合式包装组合
CN
30.07.2014
B65D 25/14 Loading...
B65D 25/14
Loading...
201420129938.9
江苏吴中医药集团有限公司
孙田江
B65D 25/14
Loading...
本实用新型涉及一种粉针剂复合式包装组合，包括：药物瓶，用于保存粉针剂药物；溶媒瓶，用于保存所述粉针剂药物的专用溶媒；遮光座，所述遮光座的内部设有适于所述药物瓶及所述溶媒瓶容纳固定的固定腔；在所述固定腔内部设有缓冲槽，所述缓冲槽的延伸方向与所述固定腔的延伸方向垂直；所述遮光座为黑色塑料质遮光座。本实用新型的粉针剂复合式包装组合，既能实现粉针剂药物与专用溶媒良好的相容性，方便临床使用，又能对药物进行避光保存、在贮藏过程中可实现保持良好的稳定性。
14. WO/2013/037127 ANTITUMOUR PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO
21.03.2013
A61K 31/573 Loading...
A61K 31/573
Loading...
PCT/CN2011/079757
INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES
LIU, Xiujun
A61K 31/573
Loading...
The present invention belongs to the field of medical chemistry, and relates to an antitumour pharmaceutical composition and use thereof. In particular, the pharmaceutical composition to which the present invention relates comprises two or three ingredients of the following three ingredients A, B and C: A. dipyridamole and/or pharmaceutically acceptable derivatives thereof; B. ubenimex and/or pharmaceutically acceptable derivatives thereof; C. dexamethasone and/or pharmaceutically acceptable derivatives thereof; optionally, the pharmaceutical composition also comprises a pharmaceutically acceptable carrier or excipient. The present invention also relates to a use of the pharmaceutical composition in preparing the antitumour drug and an antitumour method. The antitumour pharmaceutical composition in the present invention achieves the purpose of treating tumours effectively primarily by acting on the tumour microenvironment, and the features of the drug adjusting the tumour microenvironment are that it is acting on multiple targets and multiple paths, which can be expected to relieve the toxic and side effects caused by cytotoxic drugs.
15. WO/2013/037129 ANTITUMOUR PHARMACEUTICAL COMPOSITION WITH TWO ACTIVE COMPONENTS AND USE THEREOF
WO
21.03.2013
A61K 31/573 Loading...
A61K 31/573
Loading...
PCT/CN2011/079761
INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES
LIU, Xiujun
A61K 31/573
Loading...
The present invention belongs to the field of medical chemistry, and relates to an antitumour pharmaceutical composition with two active components and the use thereof. In particular, the pharmaceutical composition to which the present invention relates comprises a first independent group of active ingredients and a second independent group of active ingredients, wherein the first group of active ingredients comprises two or three ingredients of the following three ingredients A, B and C: A. dipyridamole and/or pharmaceutically acceptable derivatives thereof; B. ubenimex and/or pharmaceutically acceptable derivatives thereof; C. dexamethasone and/or pharmaceutically acceptable derivatives thereof. The second group of active ingredients comprises one or more ingredients selected from paclitaxel, adriamycin, cisplatinum, mitomycin, fluorouracil, gemcitabine, capecitabine and tyrosine kinase inhibitor; optionally, the pharmaceutical composition also comprises a pharmaceutically acceptable carrier or excipient. The antitumour pharmaceutical composition in the present invention acts on multiple targets and multiple paths, which has a clear and significant antitumour effect.
16. 102973500 一种利奈唑胺液体制剂及其制备方法
CN
20.03.2013
A61K 9/08 Loading...
A61K 9/08
Loading...
201210567227.5
江苏吴中苏药医药开发有限责任公司
许文婧
A61K 9/08
Loading...
本发明涉及的是一种利奈唑胺和氯化钠的液体制剂及其制备方法。一种含利奈唑胺液体制剂，其特征在于：包括含有下列分子式代表的化合物利奈唑胺和氯化钠的水性溶液：；所述利奈唑胺的含量为0.2-2.0%（w/v）；所述氯化钠的含量是0.5-1.0%（w/v）。
17. 101812104 New method for continuously operating to synthesize capecitabine
CN
25.08.2010
C07H 19/06 Loading...
C07H 19/06
Loading...
201010150977.3
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Cao Qingxian
C07H 19/06
Loading...
The invention relates to a new method for continuously operating to synthesize capecitabine, which is characterized in that 5-flucytosine is subjected to acylation, condensation and hydrolysis to synthesize the capecitabine. The invention has the advantages of reasonable reaction sequence, continuous operation of three steps, operation simplification, high yield, low cost and less pollution.
18. 101773578 Vitex oil nanoemulsion and preparation method thereof
CN
14.07.2010
A61K 36/85 Loading...
A61K 36/85
Loading...
201010130295.6
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Cao Qingxian
A61K 36/85
Loading...
The invention relates to a vitex oil nanoemulsion and a preparation method and application thereof. The preparation method is characterized in that the advanced nanotechnology is used for the formula and process design of the vitex oil nanoemulsion. The preparation method comprises the steps that: vitex oil, medium chain fatty acid triglyceride, soy lecithin, ethanol and the like are evenly mixed to be used as an oil phase; poloxamer is mixed with water and the like to be used as a water phase; the oil phase is added to the water phase to be mixed and emulsified at a temperature of 40 to 60 DEG C and be treated by a two-step high-pressure homogenizer to obtain the milk-white vitex oil nanoemulsion with the average particle size of less than 100nm. The vitex oil nanoemulsion prepared by the invention has high quality, reliable quality stability and good biocompatibility, and simultaneously has good expectorant, antitussive and antiasthmatic effects.
19. 101461882 Extract of Pericarpium trichosanthis and Allium macrostemon, and preparation method thereof
CN
24.06.2009
A61K 36/8962 Loading...
A61K 36/8962
Loading...
200910028024.7
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Gu Wei
A61K 36/8962
Loading...
The invention discloses a trichosanthes bark and allium macrostemon extract and a preparation method thereof. The composition is prepared by adopting the following steps: mixing trichosanthes bark with allium macrostemon in the weight proportion of 2:1 to 1:1; adding water or C1-3 ethanol with the concentration less than 50 percent for extraction; extracting an extracted solution by ion exchange resin and macroporous absorbent resin; extracting 50 to 90 weight portions of components from trichosanthes bark and the ion exchange resin of allium macrostemon; extracting 10 to 50 weight portions of components from the trichosanthes bark and macroporous resin of the allium macrostemon; mixing the two components; and obtaining the extract. The extract is applied to preparing medicines for treating diseases of cardiovascular system, and has determined curative efficacy; moreover, the extract reaches the goal of reducing dose without reducing medicine efficacy and has an extensive application prospect.
20. 101254174 Freeze-dried injection containing carbazochrome sodium sulfonate and method of preparing the same
CN
03.09.2008
A61K 9/19 Loading...
A61K 9/19
Loading...
200710191009.5
Suzhou Sixth Pharmaceutical Plant of Jiangsu Wuzhong Pharmaceutical Group Co., L
Liu Fengzhen
A61K 9/19
Loading...
The invention relates to the pharmaceutical preparation field, particularly to carbazochrome sodium sulfonate lyophilized powder for injection, which is characterized in that the stability of carbazochrome sodium sulfonate is improved by adding thiourea and/or sodium formaldehyde sulfoxylate, the solubility of the lyophilized powder for injection is improved by adding mannitol, and the obtained carbazochrome sodium sulfonate lyophilized powder for injection has stable quality.
21. 101224274 Medicine compounds of pericarp trichosanthis, longstamen onion bulb extract and preparing method thereof
CN
23.07.2008
A61K 36/8962 Loading...
A61K 36/8962
Loading...
200810019026.5
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Gu Wei
A61K 36/8962
Loading...
The invention discloses a medicine combination of snakegourd peel extract and allium macrostemon extract. The medicine combination is composed of 50-90 parts of snakegourd peel extract and 10-50 parts of allium macrostemon extract by weight; wherein, the total amino acid content in the snakegourd peel extract is not less than 50 percent, if calculated according to arginine, and the total saponin content in the allium macrostemon extract is not less than 50 percent, if calculated according to dioscin. The combination has stable quality, and high content of effective ingredients; the technique of the preparation method of the invention is stable, and has good reproduction quality. Proved by pharmacological tests, the combination has better protective effect on acute myocardial ischemia caused by rat hypophysin and canine myocardial ischemia due to coronary artery ligation. The medicine combination of the invention has promising application prospect in the respect of treating cardiovascular system diseases.
22. 101220082 Extraction and purification process for recombinant protein
CN
16.07.2008
C07K 1/14 Loading...
C07K 1/14
Loading...
200810056955.3
Jiangsu Wuzhong Group Suzhou Zhongkai Biological Pharmaceutical Co., Ltd.
Rong Zhigang
C07K 1/14
Loading...
The invention relates to a recombinant protein extraction and purification method, comprising engineering bacteria fermentation, engineering bacteria fragmentation, inclusion body washing, recombinant protein denaturation and purification, second recombinant protein denaturation and purification, denaturized recombinant protein renaturation, renaturated recombinant protein placing, ion exchange chromatography and molecular sieve chromatography, wherein, the renaturation recombinant protein is placed for 5 to 8 days under the temperature of 2 to 8 DEG C. The recombinant protein extraction and purification method improves the total yield of the recombinant protein, correspondingly improves the purity and efficiency of the final products, reduces the production cost and is beneficial to large scale industrial production.
23. 101220081 Extraction and purification process for recombinant protein
CN
16.07.2008
C07K 1/14 Loading...
C07K 1/14
Loading...
200810056952.X
Jiangsu Wuzhong Group Suzhou Zhongkai Biological Pharmaceutical Co., Ltd.
Rong Zhigang
C07K 1/14
Loading...
The invention relates to a recombinant protein extraction and purification method, comprising engineering bacteria fermentation with high density formula culture medium, engineering bacteria fragmentation, inclusion body washing, recombinant protein denaturation and purification, second recombinant protein denaturation and purification, denaturized recombinant protein renaturation, ion exchange chromatography and molecular sieve chromatography, wherein, the high density formula culture medium comprises 5 to 15g/L tryptone, 15 to 25g/L yeast extract, 7.5 to 17.5g/L hydrolyze enzyme protein, 1 to 9g/L KH2PO4 and 10 to 20g/L dextrose. The recombinant protein extraction and purification method improves the total yield of the recombinant protein, correspondingly improves the purity and efficiency of the final products, reduces the production cost and is beneficial to large scale industrial production.
24. 101053662 Nonsteroidal antiinflammatories with nitric oxide donors and its preparation method
CN
17.10.2007
C07D 271/04 Loading...
C07D 271/04
Loading...
200710021834.0
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Wu Wei
C07D 271/04
Loading...
The invention relates to a non-steroidal anti-inflammatory drug with nitrogen oxide donor and a method for preparing same, which can be used to eliminate inflammation, relieve fever and stop pain, and can decrease the frequently seen side effect thereof on the gastrointestinal tract. The structure of which is A-O(X)-CO-O(y)-B-ONO2,wherein, A is the non-steroidal anti-inflammatory group; B is the connection group, when x=0, y=1; when x=1 then y=0. The the non-steroidal anti-inflammatory groups includes aspirin, diclofenac, indometacin, lumiracoxib, brufen, ketoprofen, naproxen, piroxicam, and meloxicam. The preparation process are that the bromhydrin (or hydroxybenzene) reacts with silver nitrate into hydroxy nitrate, then reacts with bromo acid into the connection group of nitrogen oxide donor, then connects with the non-steroidal anti-inflammatory drug; or the non-steroidal anti-inflammatory drug condensates with bromo acid into a bromide intermediate, then reacts with silver nitrate into the non-steroidal anti-inflammatory drug with nitrogen oxide donor.
25. 1891717 Chemical modification method of endostatin and its use
CN
10.01.2007
C07K 17/02 Loading...
C07K 17/02
Loading...
200510040941.9
Nanjing Univ.
Wang Xinchang
C07K 17/02
Loading...
The invention belongs to the field of bio-pharmaceutical products, which provides a chemical modification method for recombinate human rh-Endostatin ('rh-ES' is called for short) through the way of using mPEG-propionaldehyde to be combined on the fixed point of free amino of N-terminal amino acid of rh-ES. Mono-PEG-rhES is the output material, its purity meet the requirements of biological products. It plays a key role in the hydrolysis resistance of trypsin and chymotrypsin, it can be used as long-acting formulations for its stability for pH and temperature and there is a great perspective in the clinical treatment of cancer.
26. 1847252 Prepn process and medicinal composition of amorphous Adefovir dipivoxil
CN
18.10.2006
C07F 9/6561 Loading...
C07F 9/6561
Loading...
200610040214.7
Jiangsu Wuzhong Suyao Medicine Development Co., Ltd.
Zhou Qin
C07F 9/6561
Loading...
The present invention relates to preparation process and medicinal composition of amorphous Adeforvir dipivolxil. The amorphous Adeforvir dipivolxil preparing process includes the following steps: adding pure crystalline or oily Adeforvir dipivolxil into organic solvent with the weight ratio between Adeforvir dipivolxil and organic solvent being 1 to 1-20, dissolving at 20-80 deg.c, decompression evaporating at 20-80 deg.c to obtain foamed solid, and final vacuum drying at 20-40 deg.c. The amorphous Adeforvir dipivolxil as effective component in 2-50 wt% is further mixed with excipient(s) in 50-98 wt% to produce medicinal composition of Adeforvir dipivolxil.
27. 1839869 Use of molo glycoside in alpha-glucosaccharase inhibitor
CN
04.10.2006
A61K 31/7048 Loading...
A61K 31/7048
Loading...
200610037722.X
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Yin Min
A61K 31/7048
Loading...
The invention provides a novel Moluo glycoside with natural source as an alpha-glucosidase depressant, and discloses a process for preparing the Moluo glycoside from natural plants such as Patrinia villosa Juss. and cornus officinalis. The invention also discloses the use of Muluo in treating diabetes.
28. 1765872 2-amido-2-[2-(4-alkylphenyl)ethyl]-1,3-methyl glycol preparation method
CN
03.05.2006
C07C 209/34 Loading...
C07C 209/34
Loading...
200510095766.3
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Zhu Chongquan
C07C 209/34
Loading...
The invention provides a preparation method for (I) 2- amido -2-[2-(4- alkyl phenyl)ethyl]-1,3- propanediol, which comprises: using alkyl benzene (II) as initial material, with Lewis acid existing, to take Friedel-Crafts acylating reaction with 3- halogenated propionyl chloride and generate beta- halogenated alkylpropiophenone (IV); reducing IV by hydride to obtain 3- nitro -1-(4- alkyl phenyl) propanol (V); preparing 2- nitro -2- methylol -4-(4- alkyl phenyl)-1,4butanediol (VI) by hydroxymethylation; reducing nitro and removing benzalcoholhydroxy to VI and obtaining the objective product.
29. 1742720 Arbidol preparation and preparing method
CN
08.03.2006
A61K 31/404 Loading...
A61K 31/404
Loading...
200510094451.7
Wuzhong-Suyao Medicine Development Co., Ltd., Jiangsu
Cao Qingxian
A61K 31/404
Loading...
The present invention discloses an Abidol preparation and its preparation method. Said preparation contains Abidol quick-released portion and Abidol slow-released portion. Said invention utilizes conventional process to prepare its quick-released portion, and utilizes hydrophilic gel skeleton material or biological denudation skeleton material to prepare its slow-released portion. According to different releasing requirements the above-mentioned two portions can be mixed according to different ratio so as to obtain the invented preparation.
30. 1733738 Preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline
CN
15.02.2006
C07D 239/94 Loading...
C07D 239/94
Loading...
200510094005.6
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Zhu Chongquan
C07D 239/94
Loading...
The invention relates to a preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline, which comprises using 3,4-dimethoxybenzoic acid (II) as raw material, synthesizing 2-amido-4-methoxy-5-hydroxybenzoic acid (V), cyclizing to obtain 6-hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one (VI), directly chloridizing to obtain 4-chloro-hydroxy-7-methoxy-quinazoline (VII), reacting directly with 3-chloro-4-fluoroaniline, carrying out amination to obtain 4-(3-chloro-4-fluoroanilino)-6-hydroxy-7-methoxy-quinazoline (VIII), finally reacting with morpholinyl chloropropane to obtain Geftinat (I).
31. 1733712 Myoinositol sulfate aluminium , its preparation method and oral compositions and uses
CN
15.02.2006
C07C 305/20 Loading...
C07C 305/20
Loading...
200510094006.0
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Zhu Chongquan
C07C 305/20
Loading...
The invention relates to inositol sulfuric aluminium compound with structural formula I with inositol as basic parent nucleus and opposite oral composition. Wherein, using the esterification between inositol with structural formula II and sulphonating agent to obtain sodium salt or sylvine of inositol hexsulfuric with structural formula III, then forming with basic aluminium chloride the objective product.
32. 1733054 Dogwood fruit extract and its preparation process
CN
15.02.2006
A61K 36/40 Loading...
A61K 36/40
Loading...
200510041480.7
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Yin Min
A61K 36/40
Loading...
The invention discloses a dogwood fruit extract and the process for preparation, wherein the extract is prepared from oleanolic acid, ursolic acid, loganin and morroniside by the ratio of (1-5) : (6-12) : (12-20) : 25. The preparing process comprises the following steps: extracting dogwood fruit with alcohol, concentrating the extract and stewing at low temperature, subjecting the upper layer solid to acid and alkaline treatment, obtaining extract A, separating the lower layer clear liquid with macroscopic resin columns, obtaining extract B, finally mixing the extract A and the extract B. The prepared dogwood fruit extract can be used for treating diabetes and the complications.
33. 1709239 Gingko lactone lyophilized powder for injection and its preparing method
CN
21.12.2005
A61K 9/19 Loading...
A61K 9/19
Loading...
200510040497.0
Wuzhong Suyao Medicine Development LLC, Jiangsu
Cao Qingxian
A61K 9/19
Loading...
The present invention discloses a bilobalide freeze-dried powder injection and its preparation method. Said injection is obtained by using alkaline solution to increase solubility of bilobalide, and its preparation method includes the following steps: dissolving mannitol, disodium (calcium) ethylene diamine tetraacetate, sodium metabisulfite and sodium hydroxide by using proper quantity of injection water, heating and adding bilobalide, heat-insulating and stirring to dissolve them, adding 0.2-0.4% (w/v) of injection active carbon, heat-insulating, filtering, cooling filtrate, using 10% citric acid solution to slowly regulate pH to 8.0-9.0, adding injection water to make constant volume, filtering by using 0.22 micron micropore filter membrane to clear solution, packaging, freeze-drying, plugging and capping.
34. 1698599 Bilobalide injection and preparation method thereof
CN
23.11.2005
A61K 9/08 Loading...
A61K 9/08
Loading...
200510072466.3
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Cao Qingxian
A61K 9/08
Loading...
The invention relates to a bilobalide injection and preparation process, wherein the preparation process comprises charging hydroxypropyl-beta-cyclodextrin into water for injection, stirring to dissolve, charging bilobalide, stirring and heating to dissolve, charging chelating agent, stirring and dissolving, charging activated charcoal and straining, charging water for injection for constant volume, refining and split charging, hot-pressed sterilization.
35. 1687060 1,2,4 furodazole-phenoxyalkyl substituted derivative of iso-oxazole, preparation method and anti virus application
CN
26.10.2005
C07D 405/10 Loading...
C07D 405/10
Loading...
200510039135.X
Wuzhong Suyao Medicine Development Co., Ltd., Jiangsu
Cao Qingxian
C07D 405/10
Loading...
The present invention relates to a compound whose structure formula is provided by said invention, pharmaceutically-acceptable salt, its preparation method and its application in preparation of medicine for curing picornavirus infection.
36. 1594319 Process for extracting ginkgolide, ginkgolide injection and process for preparing same
CN
16.03.2005
C07D 493/22 Loading...
C07D 493/22
Loading...
200410041120.2
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd.
Cao Qingxian
C07D 493/22
Loading...
The invention discloses a process for extracting ginkgolide, ginkgolide injection and process for preparing same, wherein the extracting process consists of disintegrating the ginkgo leaves, leaching by diluted acetone solution, recovering acetone, removing impurities, extracting and purifying with acetic ether, removing impurities with sodium acetate again, reclaiming acetic ether, recrystallizing in ethanol or methanol, filtering, low temperature drying, solubilizing the bilobalide with hydroxypropyl-beta-cyclodextrin to obtain the bilobalide injection.
37. 1513838 Pot cooking sythesis method of alipyracole
CN
21.07.2004
C07D 211/76 Loading...
C07D 211/76
Loading...
03132278.6
Wuzhong Medicine Development Co., Ltd., Jiangsu
Li Jinyu
C07D 211/76
Loading...
A process for preparing aripipeazole by boiling-in-a-pot method features that the three main structure units for its molecular structure are assembled together at the same time. Its advantages are short period, high productivity and low cost.

